Home › Bronchiolitis Obliterans Syndrome › NCT05919511
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
RecruitingObservational study
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria:
* Age ≥ 18 years inclusive at the time of signing the ICF
* Allogeneic SCT 90 to 180 days prior to enrollment
* Able to comprehend and willing to provide informed consent
* Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel
Exclusion Criteria:
* There are no exclusion criteria for this study
About the study
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
What is being tested
- Non-Interventional (other)
Sponsor: Incyte Corporation · Participants: 1,500 · Started: Aug 1, 2023
Contact the study team
Official record on ClinicalTrials.gov — NCT05919511
Locations in the U.S.
| Alabama | University of Alabama Birmingham, Birmingham |
| Arizona | Mayo Clinic Arizona, Phoenix |
| California | City of Hope, Duarte
USC Norris Comprehensive Cancer Center, Los Angeles |
| Colorado | University of Colorado, Aurora
Colorado Blood Cancer Institute/Presbyterian St. Luke's, Denver |
| Florida | Mayo Clinic Jacksonville, Jacksonville
AdventHealth Orlando, Orlando
Moffit Cancer Center, Orlando |
| Georgia | Emory University, Atlanta
Georgia Cancer Center, Augusta |
| Illinois | Northwestern University, Chicago
Rush University Medical Group, Chicago
The University of Chicago, Chicago
Loyola University Medical Center, Maywood |
| Kansas | The University of Kansas Clinical Research Center, Fairway |
| Maryland | University of Maryland Medical Center, Baltimore |
| Massachusetts | Massachusetts Cancer Research Center, Boston |
| Michigan | Karmanos Cancer Institute, Detroit
Corewell Health, Grand Rapids |
| Minnesota | Mayo Clinic Rochester, Rochester |
| New Jersey | Rutgers Cancer Institute of New Jersey, New Brunswick |
| New York | Memorial Sloan Kettering Cancer Center, New York |
| North Carolina | University of North Carolina at Chapel Hill, Chapel Hill
Levine Cancer Institute, Charlotte |
| Ohio | The Ohio State University, Columbus |
| Oregon | Oregon Health Sciences University, Portland |
| Pennsylvania | Geisinger Health Systems, Danville |
| Tennessee | Tristar Centennial Blood & Marrow Transplant, Nashville
Vanderbilt University Medical Center, Nashville |
| Texas | Sarah Cannon Blood Cancer Center at St. Davids's South Austin Medical Center, Austin
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
Methodist Hospital, San Antonio |
| Utah | University of Utah, Huntsman Cancer Institute, Salt Lake City |
| Washington | Fred Hutchinson Cancer Research Center, Seattle |
| Wisconsin | Medical College of Wisconsin, Milwaukee |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.